Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease

Topic: Disease mechanisms in lab and animal studies

The premise of this review is that apolipoprotein (apo) E4 is much more than a contributing factor to neurodegeneration. ApoE has critical functions in redistributing lipids among CNS cells for normal lipid homeostasis, repairing injured neurons, maintaining synapto-dendritic connections, and scavenging toxins. In multiple pathways affecting neuropathology, including Alzheimer's disease, apoE acts directly or in concert with age, head injury, oxidative stress, ischemia, inflammation, and excess amyloid beta peptide production to cause neurological disorders, accelerating progression, altering prognosis, or lowering age of onset. We envision that unique structural features of apoE4 are responsible for apoE4-associated neuropathology. Although the structures of apoE2, apoE3, and apoE4 are in dynamic equilibrium, apoE4, which is detrimental in a variety of neurological disorders, is more likely to assume a pathological conformation. Importantly, apoE4 displays domain interaction (an interaction between the N- and C-terminal domains of the protein that results in a compact structure) and molten globule formation (the formation of stable, reactive intermediates with potentially pathological activities). In response to CNS stress or injury, neurons can synthesize apoE. ApoE4 uniquely undergoes neuron-specific proteolysis, resulting in bioactive toxic fragments that enter the cytosol, alter the cytoskeleton, disrupt mitochondrial energy balance, and cause cell death. Our findings suggest potential therapeutic strategies, including the use of "structure correctors" to convert apoE4 to an "apoE3-like" molecule, protease inhibitors to prevent the generation of toxic apoE4 fragments, and "mitochondrial protectors" to prevent cellular energy disruption.

Key findings

• Importantly, apoE4 displays domain interaction (an interaction between the N- and C-terminal domains of the protein that results in a compact structure) and molten globule formation (the formation of stable, reactive intermediates with potentially pathological activities).
• Our findings suggest potential therapeutic strategies, including the use of "structure correctors" to convert apoE4 to an "apoE3-like" molecule, protease inhibitors to prevent the generation of toxic apoE4 fragments, and "mitochondrial protectors" to prevent cellular energy disruption.

New to this subject? Start with our plain-English guide: Genetics →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1073/pnas.0600549103
• PubMed: 16567625
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{mahley2006-16567625,
  author  = {Mahley, R. W. and Weisgraber, K. H. and Huang, Y.},
  title   = {{Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease}},
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  year    = {2006},
  doi     = {10.1073/pnas.0600549103},
  pmid    = {16567625},
  url     = {https://doi.org/10.1073/pnas.0600549103}
}

Related studies in Genetics

• Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease The Journal of biological chemistry · 2010-11-30 · usefulness score 48/100
• Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease? Therapeutic advances in chronic disease · 2022-03-17 · usefulness score 41/100
• Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease Communications biology · 2022-10-08 · usefulness score 52/100
• ApoE Lipidation as a Therapeutic Target in Alzheimer's Disease International journal of molecular sciences · 2020-09-01 · usefulness score 39/100
• Apolipoprotein E, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region Human Molecular Genetics · 1994-01-01 · usefulness score 48/100
• Apolipoprotein E: risk factor for Alzheimer disease American journal of human genetics · 1994-04-01 · usefulness score 45/100

Similar studies

• Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders 2016 · Genetics
• Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases 2014 · Genetics
• Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches 2023 · Genetics
• The cell biology of APOE in the brain 2024 · Genetics
• Understanding the Role of ApoE Fragments in Alzheimer's Disease 2019 · Genetics
• Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease 2020 · Genetics

More on Genetics

• A review that covers this ground Apolipoprotein e sets the stage: response to injury triggers neuropathology Neuron · 2012-12-06 · usefulness score 38/100
• Newest in this subject APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model Research Square · 2026-10-31 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Integrative systems biology identifies shared neuroimmune co-expression programmes across pulmonary tuberculosis and Alzheimer's disease Research Square · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Genetics →